LONDON, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) (the Company) today announced that it has formally notified The Nasdaq Stock Market LLC (Nasdaq) of its intention to voluntarily delist its American Depositary Shares (ADSs) from Nasdaq and its intent to deregister its ADSs from the Securities and Exchange Commission (SEC) under Section 12(b) of the Securities Exchange Act of 1934 (Exchange... Read More

Proprietary data and samples from TRACERx and Achilles’ Material Acquisition Platform (MAP) will be transferred to AstraZeneca under the Transaction Conclusion of Strategic Review LONDON, Dec. 24, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that it has transferred the commercial license of data and samples from the TRACERx® Non-Small Cell Lung Cancer (NSCLC) study to AstraZeneca... Read More

LONDON, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced that on November 15, 2024, the Listing Qualifications department of the Nasdaq Stock Market LLC ("Nasdaq") approved the Company's request to transfer the listing of the Company's American Depositary Shares (the "ADSs") from the Nasdaq Global Market to the Nasdaq Capital Market. The transfer is expected to take effect at the... Read More

Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 LONDON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates. Corporate Updates Following the discontinuation of its TIL-based cNeT program and closure of the... Read More

Achilles to discontinue development of TIL-based cNeT therapy Cash position of $95.1 million as of June 30, 2024 BofA Securities engaged to provide strategic financial advice LONDON, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL) today announced the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials. The Company will refocus its strategy... Read More

Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles’ AI-powered, tumor-targeting technology Provided interim Phase I/IIa update on the use of cNeT in Advanced NSCLC and Melanoma including first patients with enhanced host conditioning (EHC), with the first three EHC patients showing improved cNeT persistence and engraftment Cash position of $95.1... Read More

Combines Achilles’ best-in-class AI-driven, tumor-targeting technology with Arcturus’ world-leading self-amplifying mRNA platform Combined technologies have the potential to generate potent and durable T cell responses in pre-clinical IND-enabling studies LONDON, May 22, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell... Read More

LONDON, May 17, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on May 16, 2024 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 minimum bid price requirement... Read More

Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma Evaluating the benefit of enhanced host conditioning with further data expected in 2H 2024 Strong cash position of $112.3 million supports operations through 2025 LONDON, May 08, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T... Read More

Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma Improved VELOS™ manufacturing process delivering higher cNeT doses Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 Strong cash position of $131.5 million supports operations through 2025 LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc... Read More

Improved VELOS™ manufacturing process delivering higher cNeT doses Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 First three patients dosed in CHIRON and THETIS with enhanced host chemo-conditioning, along with IL-2 aligned to standard TIL therapy, show improved cNeT persistence and engraftment LONDON, April 04, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics... Read More

LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company will be presenting at the following conference: 10th Annual Immuno-Oncology 360 Conference (IO360) Speaker: Sergio Quezada, PhD, Chief Scientific Officer Presentation:... Read More

LONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced publication of a ‘Comment’ in Nature Cancer that outlines the vast potential of neoantigen immunogenicity prediction, discusses current limitations in the field that limit performance,... Read More

On track to dose 15-20 patients with higher dose cNeT by year-end 2023 Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1 2024 with additional data available in mid-2024 Strong cash position of $140 million supports operations through 2025 LONDON, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical... Read More

LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on September 20, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 minimum bid price... Read More

Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma neoRanker™ immunogenicity prediction module of PELEUS™ increases the likelihood of identifying multiple memory T cell responses Strong cash position of $144 million supports operations through 2025 LONDON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a... Read More

LONDON, June 12, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that the Company will be taking part in the following conferences in June: SAE Media Group Inaugural Cell and Gene Therapy Conference, London, United Kingdom Sergio Quezada, PhD, Chief Scientific Officer, will... Read More

Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 Strong cash position of $158.5 million supports operations into mid-2025 LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal... Read More

LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today announced that the Company’s new AI application, trained with proprietary real-world data, outperformed current AI and non-AI state-of-the-art methods for neoantigen immunogenicity prediction in... Read More

LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal neoantigens to treat solid tumors, today disclosed that the Company received notice on April 21, 2023 from the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not currently in compliance with the $1.00 minimum bid price... Read More

Patent broadly covers technology to select neoantigens that are presented by HLA molecules determined to be present in a patient’s tumor Patent applies to any modality, including vaccine and autologous T cell therapy LONDON, April 25, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today... Read More

LONDON, April 17, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, and Dr. Ed Samuel, EVP, Technical Operations, will participate in a fireside chat at Chardan’s 7th Annual Genetic Medicines and Cell Therapy Manufacturing Summit on... Read More

Demonstrated early proof-of-concept for cNeT therapy in heavily pre-treated advanced NSCLC patients Exhibited power of translational science platform by correlating anti-tumor activity of cNeT with targeting of clonal neoantigens Strong cash position of $173.3 million supports operations into mid-2025 LONDON, March 07, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical... Read More

LONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41 st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 am PST. The event will be held at the Westin St. Francis Hotel... Read More

Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC Safety and tolerability profile potentially expands opportunity to include patients ineligible for high dose lymphodepletion or high dose IL-2 Mechanism of action informed by translational science platform’s capability to correlate cNeT with anti-tumor... Read More

Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy Updated interim Phase I/II results show encouraging safety and tolerability profile with potential for deep and durable responses in NSCLC with cNeT and reduced-dose lymphodepletion and IL-2 Company to host a conference call and webcast on December 6, 2022 at 8:00am ET... Read More